Tonix Pharmaceuticals Bolsa (NASDAQ: TNXP)

Tonix Pharmaceuticals (NASDAQ:TNXP) Bolsa, Quote.MetaTitle.unusual-options

Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals Holding Corp

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Crescent Biopharma

Compugen

Coherus Oncology

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

Forte Biosciences

Fennec Pharmaceuticals Inc. - Common Stock

Fennec Pharmaceuticals

Genfit

Genelux

Heron Therapeutics

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Seres Therapeutics

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nuvectis Pharma

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Exagen

Tonix Pharmaceuticals (TNXP) Previsión

Noticias

Beneficios

Opciones

Calificaciones de analistas

Operaciones de insiders

Interés en corto

Informe de acciones

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Comments

Tonix Pharmaceuticals Opciones Inusuales

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL